ATE323478T1 - Pharmazeutische pellets enthaltend tamsulosin sowie deren herstellungsverfahren - Google Patents

Pharmazeutische pellets enthaltend tamsulosin sowie deren herstellungsverfahren

Info

Publication number
ATE323478T1
ATE323478T1 AT02786241T AT02786241T ATE323478T1 AT E323478 T1 ATE323478 T1 AT E323478T1 AT 02786241 T AT02786241 T AT 02786241T AT 02786241 T AT02786241 T AT 02786241T AT E323478 T1 ATE323478 T1 AT E323478T1
Authority
AT
Austria
Prior art keywords
tamsulosine
production process
pellets containing
pharmaceutical pellets
pharmaceutical
Prior art date
Application number
AT02786241T
Other languages
English (en)
Inventor
Johannes Jan Platteeuw
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23131212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE323478(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Application granted granted Critical
Publication of ATE323478T1 publication Critical patent/ATE323478T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02786241T 2002-11-14 2002-12-12 Pharmazeutische pellets enthaltend tamsulosin sowie deren herstellungsverfahren ATE323478T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/293,940 US7018658B2 (en) 2002-11-14 2002-11-14 Pharmaceutical pellets comprising tamsulosin

Publications (1)

Publication Number Publication Date
ATE323478T1 true ATE323478T1 (de) 2006-05-15

Family

ID=23131212

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02786241T ATE323478T1 (de) 2002-11-14 2002-12-12 Pharmazeutische pellets enthaltend tamsulosin sowie deren herstellungsverfahren
AT0000203U AT6542U1 (de) 2002-11-14 2003-01-02 Tamsulosinpellets und verfahren zum herstellen derselben

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT0000203U AT6542U1 (de) 2002-11-14 2003-01-02 Tamsulosinpellets und verfahren zum herstellen derselben

Country Status (23)

Country Link
US (1) US7018658B2 (de)
EP (1) EP1562573B1 (de)
JP (1) JP5405710B2 (de)
AT (2) ATE323478T1 (de)
AU (3) AU2002351451A1 (de)
BE (1) BE1015435A4 (de)
CA (1) CA2415840C (de)
CH (1) CH696419A5 (de)
CZ (1) CZ13341U1 (de)
DE (2) DE20219293U1 (de)
DK (2) DK1562573T3 (de)
ES (1) ES2257589T3 (de)
FI (1) FI5842U1 (de)
FR (1) FR2847166B1 (de)
GB (1) GB2395125B (de)
HU (1) HUP0500832A3 (de)
NL (1) NL1022151C2 (de)
NO (1) NO20052860L (de)
PL (1) PL206083B1 (de)
PT (1) PT1562573E (de)
SI (1) SI21394A2 (de)
WO (2) WO2004043449A1 (de)
ZA (1) ZA200503696B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
NZ535456A (en) * 2002-02-21 2006-08-31 Biovail Lab Int Srl Modified release formulations of at least one form of tramadol for oral administration
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
EA200600066A1 (ru) * 2003-07-01 2006-06-30 Крка, Товарна Здравил, Д.Д. Ново Место Тамсулозинсодержащее ядро, покрытое поливинилпирролидоном или поливинилацетатом
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
WO2005053659A1 (en) * 2003-12-03 2005-06-16 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
KR100615952B1 (ko) * 2004-05-27 2006-08-28 한국화학연구원 서방형 약물 전달 시스템
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE502004004032D1 (de) * 2004-07-14 2007-07-19 Siegfried Generics Internat Lt Granulat zur kontrollierten Freisetzung von Tamsulosin, enthaltend Alginat
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007017253A1 (de) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Orales präparat mit kontrollierter freisetzung eines benzolsulfonamids
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
KR100745515B1 (ko) * 2006-04-10 2007-08-02 주식회사 대웅제약 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법
EP2026766A1 (de) 2006-05-17 2009-02-25 Synthon B.V. Tabletten-zusammensetzung mit verlängerter freisetzung von tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
EP2047847A1 (de) * 2007-10-12 2009-04-15 KRKA, tovarna zdravil, d.d., Novo mesto Feste pharmazeutische Zusammensetzung mit Tamsulosin
WO2009047312A1 (en) * 2007-10-12 2009-04-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising tamsulosin
KR20110102339A (ko) * 2008-12-09 2011-09-16 신톤 비.브이. 고정용량 복합제용 탐술로신 펠렛
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
WO2014203137A2 (en) 2013-06-21 2014-12-24 Wockhardt Limited Pharmaceutical compositions of tamsulosin or salts thereof
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
CZ2015225A3 (cs) * 2015-03-30 2016-10-12 Zentiva, K.S. Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN105287395A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种盐酸坦索罗辛缓释微丸及其制备方法
MX2018011642A (es) 2016-03-31 2019-03-14 Hanmi Pharm Ind Co Ltd Preparacion en capsula compuesta que contiene tadalafilo y tamsulosina con estabilidad y tasa de elucion mejoradas.
EP3473244A1 (de) 2017-10-20 2019-04-24 Veru Inc. Orales tamsulosinhydrochlorid mit kontrollierter freisetzung
EP3473245A1 (de) 2017-10-20 2019-04-24 Veru Inc. Orales tamsulosinhydrochlorid mit kontrollierter freisetzung
CN118284408A (zh) 2021-10-25 2024-07-02 法玛利德尔公司 他达拉非经口混悬剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
JPS61100526A (ja) * 1984-10-22 1986-05-19 Kyowa Hakko Kogyo Co Ltd 持続性ドパミン経黒剤
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
JPH07316077A (ja) * 1994-05-20 1995-12-05 Sumitomo Pharmaceut Co Ltd 腸溶性コーティング用組成物
US6177430B1 (en) * 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
EP1064938A1 (de) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf
ID30249A (id) * 1999-08-09 2001-11-15 Yamanouchi Pharma Co Ltd Komposisi farmasi untuk terapi gejala-gejala penyakit pelaksanaan fungsi saluran air kencing bawah
JP3154710B1 (ja) * 1999-08-09 2001-04-09 山之内製薬株式会社 下部尿路症治療剤
PT1207860E (pt) * 1999-09-02 2008-01-24 Nostrum Pharmaceuticals Inc Formulação de peletes de libertação controlada
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
PT1443917E (pt) * 2001-11-07 2006-06-30 Synthon Bv Comprimidos de tamsulosina
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin

Also Published As

Publication number Publication date
AT6542U1 (de) 2003-12-29
FR2847166B1 (fr) 2005-06-10
SI21394A2 (sl) 2004-06-30
JP2006508960A (ja) 2006-03-16
HUP0500832A3 (en) 2009-12-28
FR2847166A1 (fr) 2004-05-21
EP1562573A1 (de) 2005-08-17
US20040096502A1 (en) 2004-05-20
ZA200503696B (en) 2006-08-30
JP5405710B2 (ja) 2014-02-05
PT1562573E (pt) 2006-07-31
DE60210828T2 (de) 2006-10-19
WO2004043448A1 (en) 2004-05-27
FIU20020500U0 (fi) 2002-12-16
NL1022151C2 (nl) 2004-05-18
GB0229021D0 (en) 2003-01-15
WO2004043449A1 (en) 2004-05-27
DE20219293U1 (de) 2003-06-05
CZ13341U1 (cs) 2003-06-02
PL206083B1 (pl) 2010-06-30
NO20052860L (no) 2005-08-10
FI5842U1 (fi) 2003-07-03
DK1562573T3 (da) 2006-08-21
AU2003288083A1 (en) 2004-06-03
AU2003200059A1 (en) 2004-06-03
CA2415840A1 (en) 2004-05-14
DE60210828D1 (de) 2006-05-24
GB2395125B (en) 2007-06-06
NO20052860D0 (no) 2005-06-13
AU2002351451A1 (en) 2004-06-03
PL357856A1 (en) 2004-05-17
ES2257589T3 (es) 2006-08-01
EP1562573B1 (de) 2006-04-19
HUP0500832A2 (en) 2007-07-30
GB2395125A (en) 2004-05-19
AU2003200059B2 (en) 2008-07-03
CA2415840C (en) 2008-11-18
US7018658B2 (en) 2006-03-28
CH696419A5 (de) 2007-06-15
BE1015435A4 (nl) 2005-04-05
DK200300005U3 (da) 2003-04-25

Similar Documents

Publication Publication Date Title
ATE323478T1 (de) Pharmazeutische pellets enthaltend tamsulosin sowie deren herstellungsverfahren
DE60334182D1 (de) Kubische Speichermatrix und deren Herstellungsverfahren
DE602004010785D1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
IS7881A (is) CHK-, PDK- og AKT-hindrandi pýrimidín, framleiðsla þeirra og notkun sem lyfjaefni
DE60226704D1 (de) Acylierte 6,7,8,9-tetrahydro-5h-benzocycloheptenyl-amine und deren pharmazeutische verwendung
NO20031776L (no) Null-boringskomplettering og produksjonssystem
FI7846U1 (fi) Farmaseuttinen valmiste, joka sisältää oksikodonia ja naloksonia
DE60316552D1 (de) Tablette mit hohem wirkstoffgehalt
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
IL166039A0 (en) New effector conjugates process for their production and their pharmaceutical use
DE60312603D1 (de) Mikrokapsel sowie das Herstellungsverfahren
ATE367152T1 (de) Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung
SG116507A1 (en) Pharmaceutical dosage form and method of making.
DE60306074D1 (de) Mikrokapsel sowie Herstellungsverfahren
AU2003288308A1 (en) Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin
ATE434435T1 (de) Pharmazeutische zubereitungen enthaltend modafinil
ATE354356T1 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
ATE453390T1 (de) Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
ATE507831T1 (de) Melatonin enthaltende pharmazeutische formulierung
DE602004019809D1 (de) Pharmazeutische zusammensetzung, vinflunin enthaltend, zur parenteralen verabreichung, deren herstellungsverfahren und anwendung
DE60329614D1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
DE602004022169D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE290543T1 (de) Pharmazeutische zusammensetzungen mit oligosacchariden und deren herstellung
GB0624498D0 (en) Pharmaceutical compositon containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1562573

Country of ref document: EP